What is JBIO's capex?

JBIO (JBIO) reported capex of $3K in Q4 2025.

What is the long-term trend for JBIO's capex?

Over 3 years (2021 to 2025), JBIO's capex has grown at a 2.7% compound annual growth rate (CAGR), from $181K to $196K.

What does capex mean?

Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

JBIO JBIO CapEx

CapEx at other companies

Vertex PharmaceuticalsVRTX

$133.4M+228%

Vera TherapeuticsVERA

$23K-87.7%

AnaptysBio, Inc.ANAB

$17K-51.4%

Cullinan Therapeutics, Inc.CGEM

$11K—

Viridian Therapeutics, Inc.VRDN

$23K-73.3%

AnnexonANNX

$0-100%

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B—

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: JBIO’s 10-K, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's capex?: JBIO (JBIO) reported capex of $3K in Q4 2025.
What is the long-term trend for JBIO's capex?: Over 3 years (2021 to 2025), JBIO's capex has grown at a 2.7% compound annual growth rate (CAGR), from $181K to $196K.
What does capex mean?: Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.